/manager/Index ${session.getAttribute("locale")} 5 Design and synthesis of arylhydrocarbon receptor ligands for the treatment of breast cancer /manager/Repository/uon:36694 Wed 24 Jun 2020 17:13:55 AEST ]]> Evaluation of associations between genetically predicted circulating protein biomarkers and breast cancer risk /manager/Repository/uon:37129 via the integration of genomics and proteomics data. In the Breast Cancer Association Consortium (BCAC), with 122,977 cases and 105,974 controls of European descendants, we evaluated the associations of the genetically predicted concentrations of >1,400 circulating proteins with breast cancer risk. We used data from a large-scale protein quantitative trait loci (pQTL) analysis as our study instrument. Summary statistics for these pQTL variants related to breast cancer risk were obtained from the BCAC and used to estimate odds ratios (OR) for each protein using the inverse-variance weighted method. We identified 56 proteins significantly associated with breast cancer risk by instrumental analysis (false discovery rate <0.05). Of these, the concentrations of 32 were influenced by variants close to a breast cancer susceptibility locus (ABO, 9q34.2). Many of these proteins, such as insulin receptor, insulin-like growth factor receptor 1 and other membrane receptors (OR: 0.82-1.18, p values: 6.96 × 10-43.28 × 10-8), are linked to insulin resistance and estrogen receptor signaling pathways. Proteins identified at other loci include those involved in biological processes such as alcohol and lipid metabolism, proteolysis, apoptosis, immune regulation and cell motility and proliferation. Consistent associations were observed for 22 proteins in the UK Biobank data (p < 0.05). The study identifies potential novel biomarkers for breast cancer, but further investigation is needed to replicate our findings.]]> Wed 19 Aug 2020 12:59:44 AEST ]]> Postmastectomy radiation therapy in women with T1-T2 tumors and 1 to 3 positive lymph nodes: analysis of the Breast International Group 02-98 Trial /manager/Repository/uon:32260 Wed 16 May 2018 15:44:20 AEST ]]> Phosphorylation of calcium/calmodulin-stimulated protein kinase II at T286 enhances invasion and migration of human breast cancer cells /manager/Repository/uon:30150 Wed 13 Jan 2021 17:37:19 AEDT ]]> The muscle mass, omega-3, diet, exercise and lifestyle (MODEL) study - a randomised controlled trial for women who have completed breast cancer treatment /manager/Repository/uon:20558 Wed 11 Apr 2018 17:17:31 AEST ]]> The experience and effects of group improvisational music therapy amongst women recently diagnosed with breast cancer: a mixed methods study /manager/Repository/uon:6890 Wed 11 Apr 2018 17:11:12 AEST ]]> Prevalence of PALB2 mutations in Australian familial breast cancer cases and controls /manager/Repository/uon:27356  G variant (rs152451) was significantly enriched in cases and may represent a low-penetrance polymorphism (p = 0.002; OR 1.24 (95 % CI 1.09–1.47). Conclusions: Our findings support truncating variants in PALB2 as high-penetrance breast cancer susceptibility alleles, and suggest that a common missense variant may also lead to a low level of increased breast cancer risk.]]> Wed 11 Apr 2018 17:01:50 AEST ]]> A population-based study of breast cancer prevalence in Australia: predicting the future health care needs of women living with breast cancer /manager/Repository/uon:16777 Wed 11 Apr 2018 16:38:43 AEST ]]> GPU-FS-kNN: a software tool for fast and scalable kNN computation using GPUs /manager/Repository/uon:15138 Wed 11 Apr 2018 16:14:13 AEST ]]> The expression of Dicer and Drosha in matched normal tissues, tumours and lymph node metastases in triple negative breast cancer /manager/Repository/uon:20669 Wed 11 Apr 2018 15:57:11 AEST ]]> Sortilin is associated with breast cancer aggressiveness and contributes to tumor cell adhesion and invasion /manager/Repository/uon:27772 Wed 11 Apr 2018 15:54:06 AEST ]]> Chemotaxis towards hyaluronan is dependent on CD44 expression and modulated by cell type variation in CD44-hyaluronan binding /manager/Repository/uon:1383 Wed 11 Apr 2018 15:51:49 AEST ]]> The contribution of genetic susceptibility to breast cancer /manager/Repository/uon:15177 Wed 11 Apr 2018 15:26:00 AEST ]]> Metabolic, health and lifestyle profiling of breast cancer radiotherapy patients and the risk of developing fatigue /manager/Repository/uon:17019 Wed 11 Apr 2018 15:14:52 AEST ]]> Docosahexaenoic acid inhibits the invasion of MDA-MB-231 breast cancer cells through upregulation of cytokeratin-1 /manager/Repository/uon:27950 in vitro invasion assays showed that siRNA against KRT1 was able to reverse the DHA-induced inhibition of breast cancer cell invasion. In conclusion, KRT1 is involved in the anti-invasive activity of DHA in breast cancer cells.]]> Wed 11 Apr 2018 15:01:51 AEST ]]> The role of short tandem repeats in genetic susceptibility to breast and endometrial cancers /manager/Repository/uon:23272 Wed 11 Apr 2018 14:52:43 AEST ]]> Prediction of breast cancer risk based on profiling with common genetic variants /manager/Repository/uon:28423 Wed 11 Apr 2018 14:49:25 AEST ]]> The subclonal architecture of metastatic breast cancer: results from a prospective community-based rapid autopsy program "CASCADE" /manager/Repository/uon:29735 Wed 11 Apr 2018 14:45:58 AEST ]]> Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride /manager/Repository/uon:17045 Wed 11 Apr 2018 14:36:26 AEST ]]> A polymorphic repeat in the IGF1 promoter influences the risk of endometrial cancer /manager/Repository/uon:26531 Wed 11 Apr 2018 14:30:11 AEST ]]> Expanding the genetic basis of copy number variation in familial breast cancer /manager/Repository/uon:16788 55 years of age). Results: CNV analysis revealed the presence of 275 unique rearrangements that were not present in the control population suggestive of their involvement in BC risk. Several CNVs were found that have been previously reported as BC susceptibility genes. This included CNVs in RPA3, NBN (NBS1), MRE11A and CYP19A1 in five unrelated fBC patients suggesting that these genes are involved in BC initiation and/or progression. Of special interest was the identification of WWOX and FHIT rearrangements in three unrelated fBC patients. Conclusions: This study has identified a number of CNVs that potentially contribute to BC initiation and/or progression. The identification of CNVs that are associated with known tumour suppressor genes is of special interest that warrants further larger studies to understand their precise role in fBC.]]> Wed 11 Apr 2018 14:30:00 AEST ]]> Associations between physical activity and quality of life in a population-based sample of kidney cancer survivors /manager/Repository/uon:17989 Wed 11 Apr 2018 14:22:59 AEST ]]> Priorities for women with lymphoedema after treatment for breast cancer: population based cohort study /manager/Repository/uon:17670 Wed 11 Apr 2018 14:20:20 AEST ]]> Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia /manager/Repository/uon:19379 Wed 11 Apr 2018 14:19:24 AEST ]]> Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): A double-blind, randomised controlled trial /manager/Repository/uon:24206 Wed 11 Apr 2018 14:11:46 AEST ]]> Move More for Life: the development and evaluation of a computer tailored-print intervention for promoting physical activity among post-treatment breast cancer survivors /manager/Repository/uon:14185 Wed 11 Apr 2018 14:10:58 AEST ]]> Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial /manager/Repository/uon:19871 Wed 11 Apr 2018 14:09:42 AEST ]]> Move more for life: the protocol for a randomised efficacy trial of a tailored-print physical activity intervention for post-treatment breast cancer survivors /manager/Repository/uon:15193 Wed 11 Apr 2018 14:08:30 AEST ]]> Impact of deprivation on breast cancer survival among women eligible for mammographic screening in the West Midlands (UK) and New South Wales (Australia): Women diagnosed 1997-2006 /manager/Repository/uon:26117 Wed 11 Apr 2018 13:45:35 AEST ]]> Evolving wavelet neural networks for breast cancer classification /manager/Repository/uon:17067 Wed 11 Apr 2018 13:34:22 AEST ]]> Are international differences in breast cancer survival between Australia and the UK present amongst both screen-detected women and non-screen-detected women?: survival estimates for women diagnosed in West Midlands and New South Wales 1997-2006 /manager/Repository/uon:26118 Wed 11 Apr 2018 13:10:28 AEST ]]> Iteratively refining breast cancer intrinsic subtypes in the METABRIC dataset /manager/Repository/uon:23687 Wed 11 Apr 2018 13:07:25 AEST ]]> The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation /manager/Repository/uon:30577 Wed 11 Apr 2018 13:01:52 AEST ]]> Non-benzoquinone geldanamycin analogs trigger various forms of death in human breast cancer cells /manager/Repository/uon:30132 Wed 11 Apr 2018 12:53:48 AEST ]]> Participant-reported symptoms and their effect on long-term adherence in the International Breast Cancer Intervention Study I (IBIS-I) /manager/Repository/uon:29519 .05). In both treatment arms, we observed significant trends for lower adherence with increasing severity for all symptoms (P < .01) except headaches (P = .054). Conclusion: In the IBIS-I trial, experiencing predefined symptoms in the first 6 months reduced long-term adherence. Effects were similar between treatment arms, suggesting that women were attributing age-related symptoms to preventive therapy. Interventions were required to support symptom management.]]> Wed 11 Apr 2018 12:50:17 AEST ]]> The IMPAKT of breast cancer research: fundamental science and clinical medicine /manager/Repository/uon:23667 Wed 11 Apr 2018 12:36:34 AEST ]]> Basal-like breast cancer: molecular profiles, clinical features and survival outcomes /manager/Repository/uon:30824 Wed 11 Apr 2018 12:30:47 AEST ]]> Copy number variants and their role in hereditary breast cancer and hereditary colorectal cancers /manager/Repository/uon:22038 Wed 11 Apr 2018 12:26:23 AEST ]]> Physical activity and health literacy in women diagnosed with breast cancer /manager/Repository/uon:24607 Wed 11 Apr 2018 12:10:48 AEST ]]> Nerve fibers infiltrate the tumor microenvironment and are associated with nerve growth factor production and lymph node invasion in breast cancer /manager/Repository/uon:27771 In vitro, breast cancer cells were able to induce neurite outgrowth in PC12 cells, and this neurotrophic activity was partially inhibited by anti-NGF blocking antibodies. In conclusion, infiltration by nerve fibers is a feature of the tumor microenvironment that is associated with aggressiveness and involves NGF production by cancer cells. The potential participation of nerve fibers in breast cancer progression needs to be further considered.]]> Wed 11 Apr 2018 11:44:48 AEST ]]> Genetic and epigenetic changes associated with the development of lymph node metastasis in triple negative breast cancer /manager/Repository/uon:22783 Wed 11 Apr 2018 11:21:14 AEST ]]> Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer /manager/Repository/uon:14178 Wed 11 Apr 2018 11:03:59 AEST ]]> Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial /manager/Repository/uon:21643 Wed 11 Apr 2018 11:01:30 AEST ]]> A novel polymorphic repeat in the upstream regulatory region of the estrogen-induced gene EIG121 is not associated with the risk of developing breast or endometrial cancer /manager/Repository/uon:30240 EIG121) has been associated with breast and endometrial cancers, but its mechanism of action remains unknown. In a genome-wide search for tandem repeats, we found that EIG121 contains a short tandem repeat (STR) in its upstream regulatory region which has the potential to alter gene expression. The presence of this STR has not previously been analysed in relation to breast or endometrial cancer risk. Results: In this study, the lengths of this STR were determined by PCR, fragment analysis and sequencing using DNA from 223 breast cancer patients, 204 endometrial cancer patients and 220 healthy controls to determine if they were associated with the risk of developing breast or endometrial cancer. We found this repeat to be highly variable with the number of copies of the AG motif ranging from 27 to 72 and having a bimodal distribution. No statistically significant association was identified between the length of this STR and the risk of developing breast or endometrial cancer or age at diagnosis. Conclusions: The STR in the upstream regulatory region of EIG121 is highly polymorphic, but is not associated with the risk of developing breast or endometrial cancer in the cohorts analysed here. While this polymorphic STR in the regulatory region of EIG121 appears to have no impact on the risk of developing breast or endometrial cancer, its association with disease recurrence or overall survival remains to be determined.]]> Wed 11 Apr 2018 10:50:53 AEST ]]> Impact of CYO19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial /manager/Repository/uon:28241 Wed 11 Apr 2018 10:43:55 AEST ]]> DNA methylation profile of triple negative breast cancer-specific genes comparing lymph node positive patients to lymph node negative patients /manager/Repository/uon:25448 Wed 11 Apr 2018 10:40:34 AEST ]]> The regulation, function and expression of Δ40p53 in breast cancer /manager/Repository/uon:27459 Wed 11 Apr 2018 10:32:51 AEST ]]> Novel genes associated with lymph node metastasis in triple negative breast cancer /manager/Repository/uon:23916 Wed 11 Apr 2018 10:32:03 AEST ]]> Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer /manager/Repository/uon:8317 Wed 11 Apr 2018 10:31:35 AEST ]]> PRONGF/NGF and nerve infiltration in prostate and breast cancer /manager/Repository/uon:22043 Wed 11 Apr 2018 10:12:18 AEST ]]> Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials /manager/Repository/uon:23398 Wed 11 Apr 2018 10:02:15 AEST ]]> Reevaluation of the BRCA<sub>2</sub> truncating allele c.9976A > T (p.Lys3326Ter) in a familial breast cancer context /manager/Repository/uon:22707 BRCA2, has a large number of genetic variants of unknown effect. The variant rs11571833, an A > T transversion in the final exon of the gene that leads to the creation of a stop codon 93 amino acids early (K3326*), is reported as a neutral polymorphism but there is some evidence to suggest an association with an increased risk of breast cancer. We assessed whether this variant was enriched in a cohort of breast cancer cases ascertained through familial cancer clinics compared to population-based non-cancer controls using a targeted sequencing approach. We identified the variant in 66/2634 (2.5%) cases and 33/1996 (1.65%) controls, indicating an enrichment in the breast cancer cases (p = 0.047, OR 1.53, 95% CI 1.00–2.34). This data is consistent with recent iCOGs data suggesting that this variant is not neutral with respect to breast cancer risk. rs11571833 may need to be included in SNP panels for evaluating breast cancer risk.]]> Wed 11 Apr 2018 09:55:17 AEST ]]> Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial /manager/Repository/uon:20763 Wed 11 Apr 2018 09:54:54 AEST ]]> Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21 /manager/Repository/uon:7054 Wed 11 Apr 2018 09:50:49 AEST ]]> Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial /manager/Repository/uon:20549 Wed 11 Apr 2018 09:50:48 AEST ]]> Suppression of endoplasmic reticulum stress-induced invasion and migration of breast cancer cells through the downregulation of heparanase /manager/Repository/uon:14383 Wed 11 Apr 2018 09:49:12 AEST ]]> Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial /manager/Repository/uon:19496 Wed 11 Apr 2018 09:40:34 AEST ]]> Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone /manager/Repository/uon:17161 Wed 11 Apr 2018 09:14:19 AEST ]]> Cultural adaptation process of the Supportive Care Needs Survey for Mexican patients with breast cancer /manager/Repository/uon:36827 Wed 08 Jul 2020 15:05:48 AEST ]]> HER2 status predicts for upfront AI benefit: a TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2 /manager/Repository/uon:34088 Wed 06 Feb 2019 16:16:15 AEDT ]]> Treatment efficacy, adherence, and quality of life among women younger than 35 years in the International Breast Cancer Study Group TEXT and SOFT adjuvant endocrine therapy trials /manager/Repository/uon:29891 Wed 06 Feb 2019 11:42:54 AEDT ]]> Comparison of three different methods for determining cell proliferation in breast cancer cell lines /manager/Repository/uon:30103 in vitro including conventional hemocytometer counting chamber, a luminescence-based assay that utilizes the change in the metabolic activity of viable cells as a measure of the relative number of cells, and a multi-mode cell imager that measures cell number using a counting algorithm. Each method presents its own advantages and disadvantages for the measurement of cell proliferation, including time, cost and high-throughput compatibility. This protocol demonstrates that each method could accurately measure cell proliferation over time, and was sensitive to detect growth at differing cellular densities. Additionally, measurement of cell proliferation using a cell imager was able to provide further information such as morphology, confluence and allowed for a continual monitoring of cell proliferation over time. In conclusion, each method is capable of measuring cell proliferation, but the chosen method is user-dependent.]]> Wed 04 Sep 2019 10:12:09 AEST ]]> Strategies to support shared decision making in breast cancer /manager/Repository/uon:34274 Wed 04 Sep 2019 09:54:02 AEST ]]> Health literacy and physical activity in women diagnosed with breast cancer /manager/Repository/uon:31009 Wed 04 Sep 2019 09:40:16 AEST ]]> Polymorphisms in a putative enhancer at the 10q21.2 breast cancer risk locus regulate NRBF2 expression /manager/Repository/uon:28231 Wed 01 Aug 2018 14:52:20 AEST ]]> The discovery of novel biomarkers improves breast cancer intrinsic subtype prediction and reconciles the labels in the METABRIC data set /manager/Repository/uon:25143 Tue 27 Mar 2018 15:15:35 AEDT ]]> Mobile breast cancer e-support program for Chinese women with breast cancer undergoing chemotherapy (Part 2): multicenter randomized controlled trial /manager/Repository/uon:35186 Tue 25 Jun 2019 16:27:12 AEST ]]> Association analysis identifies 65 new breast cancer risk loci /manager/Repository/uon:33895 BRCA1, and many common, mostly non-coding variants. However, much of the genetic contribution to breast cancer risk remains unknown. Here we report the results of a genome-wide association study of breast cancer in 122,977 cases and 105,974 controls of European ancestry and 14,068 cases and 13,104 controls of East Asian ancestry. We identified 65 new loci that are associated with overall breast cancer risk at P < 5 × 10-8. The majority of credible risk single-nucleotide polymorphisms in these loci fall in distal regulatory elements, and by integrating in silico data to predict target genes in breast cells at each locus, we demonstrate a strong overlap between candidate target genes and somatic driver genes in breast tumours. We also find that heritability of breast cancer due to all single-nucleotide polymorphisms in regulatory features was 2-5-fold enriched relative to the genome-wide average, with strong enrichment for particular transcription factor binding sites. These results provide further insight into genetic susceptibility to breast cancer and will improve the use of genetic risk scores for individualized screening and prevention.]]> Tue 22 Jan 2019 14:37:29 AEDT ]]> Adjuvant endocrine therapy for premenopausal women: risk stratification, type and duration /manager/Repository/uon:36613 Tue 16 Jun 2020 12:01:41 AEST ]]> Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer /manager/Repository/uon:33786 -8 with ten variants at nine new loci. At P < 0.05, we replicated associations with 10 of 11 variants previously reported in ER-negative disease or BRCA1 mutation carrier GWAS and observed consistent associations with ER-negative disease for 105 susceptibility variants identified by other studies. These 125 variants explain approximately 16% of the familial risk of this breast cancer subtype. There was high genetic correlation (0.72) between risk of ER-negative breast cancer and breast cancer risk for BRCA1 mutation carriers. These findings may lead to improved risk prediction and inform further fine-mapping and functional work to better understand the biological basis of ER-negative breast cancer.]]> Tue 15 Jan 2019 11:13:41 AEDT ]]> The association between age, comorbidities and use of radiotherapy in women with breast cancer: implications for survival /manager/Repository/uon:33410 65 years of age who received RT survived significantly longer than those who did not receive RT (aHR = 0.53, 95% CI = 0.52–0.54). However, as women aged, those with comorbidities were less likely to receive RT (adjusted p-trend by age < 0.0001). Conclusions: The development of decision-making tools to assist clinicians, and older women with breast cancer and comorbidities, are needed to facilitate personalized treatment plans regarding RT. This is particularly relevant as the population ages and the number of women with breast cancer is expected to increase in the near future.]]> Tue 03 Sep 2019 18:19:20 AEST ]]> Exploring women's experiences with a decision aid for neoadjuvant systemic therapy for operable breast cancer /manager/Repository/uon:34901 Tue 03 Sep 2019 17:58:24 AEST ]]> Can models of self-management support be adapted across cancer types? A comparison of unmet self-management needs for patients with breast or colorectal cancer /manager/Repository/uon:30002 Tue 03 Sep 2019 17:57:57 AEST ]]> Molecular patterns of cancer colonisation in lymph nodes of breast cancer patients /manager/Repository/uon:33639 Tue 03 Sep 2019 17:57:36 AEST ]]> Menopausal Hormone Therapy use and breast cancer risk by receptor subtypes: results from the New South Wales Cancer Lifestyle and EvaluAtion of Risk (CLEAR) study /manager/Repository/uon:33626 Tue 03 Sep 2019 17:56:46 AEST ]]> Adjuvant systemic treatment of premenopausal women with hormone receptor-positive early breast cancer: lights and shadows /manager/Repository/uon:34779 Thu 31 Oct 2019 16:13:17 AEDT ]]> Cross-sectional survey to inform the development of a telehealth support model: a feasibility study for women undergoing breast cancer surgery /manager/Repository/uon:36903 Thu 16 Jul 2020 12:19:42 AEST ]]> Identification of breast cancer subtypes using multiple gene expression microarray datasets /manager/Repository/uon:31536 Sat 24 Mar 2018 08:44:27 AEDT ]]> Functional identification of a novel transcript variant of INPP4B in human colon and breast cancer cells /manager/Repository/uon:31508 Sat 24 Mar 2018 08:44:17 AEDT ]]> The functional role of PPP2R2A in luminal breast cancer /manager/Repository/uon:36157 Mon 26 Oct 2020 12:11:15 AEDT ]]> p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial /manager/Repository/uon:32265 Mon 23 Sep 2019 13:56:46 AEST ]]> Carcinoma of the male breast in Zambia /manager/Repository/uon:34163 female follows the general trend of lowered incidence of carcinoma of the breast for Africa, the male shows an unexpected increased incidence. Some of the possible aetiological factors have been superficially examined but no facts have been established yet to account for the relatively high male incidence.]]> Mon 23 Sep 2019 13:45:06 AEST ]]> Evolutionary wavelet neural network ensembles for breast cancer and Parkinson's disease prediction /manager/Repository/uon:32038 Mon 23 Sep 2019 13:42:04 AEST ]]> Early participant reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II /manager/Repository/uon:32258 Mon 23 Sep 2019 13:24:38 AEST ]]> A mobile application of a breast cancer e-support program for Chinese women with breast cancer undergoing chemotherapy /manager/Repository/uon:33127 Mon 23 Sep 2019 12:39:30 AEST ]]> Mobile breast cancer e-support program for Chinese women with breast cancer undergoing chemotherapy (Part 1): qualitative study of women's perceptions /manager/Repository/uon:32034 Mon 23 Sep 2019 12:04:09 AEST ]]> ProNGF, NGF and their receptors in tumour innervation and progression: a study in breast and thyroid cancers /manager/Repository/uon:31979 Mon 23 Sep 2019 11:59:37 AEST ]]> Breast cancer intrinsic subtypes: a critical conception in bioinformatics /manager/Repository/uon:30639 Mon 23 Sep 2019 11:53:06 AEST ]]> Participant-reported symptoms and their effect on long-term adherence in the International Breast Cancer Intervention Study I (IBIS I) /manager/Repository/uon:32264 .05). In both treatment arms, we observed significant trends for lower adherence with increasing severity for all symptoms (P < .01) except headaches (P = .054). Conclusion: In the IBIS-I trial, experiencing predefined symptoms in the first 6 months reduced long-term adherence. Effects were similar between treatment arms, suggesting that women were attributing age-related symptoms to preventive therapy. Interventions were required to support symptom management.]]> Mon 23 Sep 2019 11:46:30 AEST ]]> Mammographic (breast) density as a potential biomarker for endocrine trial treatment efficacy in breast cancer prevention /manager/Repository/uon:32394 Mon 23 Sep 2019 11:45:21 AEST ]]> Women's experiences with deciding on neoadjuvant systemic therapy for operable breast cancer: a qualitative study /manager/Repository/uon:32035 Mon 23 Sep 2019 11:18:09 AEST ]]> When do patient reported quality of life indicators become prognostic in breast cancer? /manager/Repository/uon:32263 Mon 23 Sep 2019 10:48:43 AEST ]]> Multifunctional nanomedicines based on albumin for targeted breast cancer therapy /manager/Repository/uon:27891 Mon 23 Sep 2019 10:12:42 AEST ]]> Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer /manager/Repository/uon:20880 Mon 11 Mar 2019 12:15:55 AEDT ]]> Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer /manager/Repository/uon:24831 -8) with oestrogen receptor (ER)-negative breast cancer and BRCA1-associated breast cancer risk. In this study, to identify new ER-negative susceptibility loci, we performed a meta-analysis of 11 genome-wide association studies (GWAS) consisting of 4,939 ER-negative cases and 14,352 controls, combined with 7,333 ER-negative cases and 42,468 controls and 15,252 BRCA1 mutation carriers genotyped on the iCOGS array. We identify four previously unidentified loci including two loci at 13q22 near KLF5, a 2p23.2 locus near WDR43 and a 2q33 locus near PPIL3 that display genome-wide significant associations with ER-negative breast cancer. In addition, 19 known breast cancer risk loci have genome-wide significant associations and 40 had moderate associations (P<0.05) with ER-negative disease. Using functional and eQTL studies we implicate TRMT61B and WDR43 at 2p23.2 and PPIL3 at 2q33 in ER-negative breast cancer aetiology. All ER-negative loci combined account for ~11% of familial relative risk for ER-negative disease and may contribute to improved ER-negative and BRCA1 breast cancer risk prediction.]]> Mon 11 Mar 2019 12:13:11 AEDT ]]> Systemic treatment of HER2+ metastatic breast cancer: clinical conundrums and future perspectives /manager/Repository/uon:19927 Mon 06 Aug 2018 11:18:23 AEST ]]> Tumor-infiltrating lymphocytes and prognosis: a poled individual patient analysis of early-stage triple-negative breast cancers /manager/Repository/uon:34339 Mon 03 Feb 2020 11:52:07 AEDT ]]> Gelatin-albumin hybrid nanoparticles as matrix metalloproteinases-degradable delivery systems for breast cancer therapy /manager/Repository/uon:34716 Fri 26 Apr 2019 15:52:16 AEST ]]> The preventable burden of breast cancers for premenopausal and postmenopausal women in Australia: A pooled cohort study /manager/Repository/uon:37400 n = 214,536) to national cancer and death registries, and estimated the strength of the associations between behaviours causally related to cancer incidence and death using adjusted proportional hazards models. We estimated exposure prevalence from representative health surveys. We combined these estimates to calculate Population Attributable Fractions (PAFs) with 95% confidence intervals (CIs), and compared PAFs for population subgroups. During the first 10 years follow‐up, there were 640 incident breast cancers for premenopausal women, 2,632 for postmenopausal women, and 8,761 deaths from any cause. Of future breast cancers for premenopausal women, any regular alcohol consumption explains 12.6% (CI = 4.3–20.2%), current use of oral contraceptives for ≥5 years 7.1% (CI = 0.3–13.5%), and these factors combined 18.8% (CI = 9.1–27.4%). Of future breast cancers for postmenopausal women, overweight or obesity (BMI ≥25 kg/m2) explains 12.8% (CI = 7.8–17.5%), current use of menopausal hormone therapy (MHT) 6.9% (CI = 4.8–8.9%), any regular alcohol consumption 6.6% (CI = 1.5–11.4%), and these factors combined 24.2% (CI = 17.6–30.3%). The MHT‐related postmenopausal breast cancer burden varied by body fatness, alcohol consumption and socio‐economic status, the body fatness‐related postmenopausal breast cancer burden by alcohol consumption and educational attainment, and the alcohol‐related postmenopausal breast cancer burden by breast feeding history. Our results provide evidence to support targeted and population‐level cancer control activities.]]> Fri 06 Nov 2020 17:34:03 AEDT ]]> The function of Δ40p53 in breast cancer /manager/Repository/uon:36560 Fri 05 Jun 2020 20:10:17 AEST ]]>